Hemopurifier®
Solid Tumors (adjunct to anti-PD-1 therapy)
Key Facts
About Aethlon Medical
Aethlon Medical is a clinical-stage biotech focused on developing its proprietary Hemopurifier® device, a lectin-affinity blood filter designed as an adjunctive therapy to remove immunosuppressive exosomes in cancer and enveloped viruses in infections. Its key achievements include securing dual FDA Breakthrough Device designations and advancing an ongoing safety and feasibility trial in oncology patients in Australia. The company's strategy leverages this regulatory pathway to accelerate development in two high-need areas, aiming to validate a platform that could enhance the efficacy of existing immunotherapies and provide a rapid-response tool for pandemic threats.
View full company profileAbout Aethlon Medical
Aethlon Medical is a clinical-stage biotech focused on developing its proprietary Hemopurifier® device, a lectin-affinity blood filter designed as an adjunctive therapy to remove immunosuppressive exosomes in cancer and enveloped viruses in infections. Its key achievements include securing dual FDA Breakthrough Device designations and advancing an ongoing safety and feasibility trial in oncology patients in Australia. The company's strategy leverages this regulatory pathway to accelerate development in two high-need areas, aiming to validate a platform that could enhance the efficacy of existing immunotherapies and provide a rapid-response tool for pandemic threats.
View full company profile